Genmab A/S (NASDAQ:GMAB) Hits New 52-Week Low - Time to Sell?

Genmab A/S (NASDAQ:GMAB - Get Free Report) shares hit a new 52-week low during mid-day trading on Monday . The company traded as low as $18.87 and last traded at $18.99, with a volume of 103803 shares. The stock had previously closed at $19.00.

Wall Street Analyst Weigh In

Several research firms recently commented on GMAB. Sanford C. Bernstein upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, December 20th. HC Wainwright reiterated a "buy" rating and set a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday. BMO Capital Markets reaffirmed an "outperform" rating and set a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Finally, Leerink Partners upgraded Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price on the stock in a research note on Thursday. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $42.17.

Genmab A/S Stock Performance

The company has a market cap of $13.83 billion, a price-to-earnings ratio of 20.30, a PEG ratio of 0.54 and a beta of 0.96. The company has a 50-day simple moving average of $20.68 and a 200-day simple moving average of $23.21.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. As a group, equities research analysts forecast that Genmab A/S will post 1.25 EPS for the current year.

Institutional Trading of Genmab A/S

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Legacy Wealth Asset Management LLC increased its holdings in Genmab A/S by 1.1% in the third quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company's stock valued at $1,097,000 after buying an additional 471 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Genmab A/S by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock worth $186,000 after acquiring an additional 827 shares during the period. EverSource Wealth Advisors LLC increased its stake in Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after purchasing an additional 939 shares in the last quarter. Lindbrook Capital LLC raised its holdings in Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after purchasing an additional 950 shares during the last quarter. Finally, GAMMA Investing LLC boosted its position in Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after purchasing an additional 1,051 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.